Ocular Therapeutix sets terms for IPO
July 11, 2014 by Brad Perriello
Ocular Therapeutix is looking to raise as much as $80 million in a forthcoming initial public offering, the company said today.
Bedford, Mass.-based Ocular Therapeutix said it plans to offer 5 million shares at $14 to $16 apiece, making the IPO worth $70 million to $80 million. Read more
Allergan renews fight against hostile Valeant takeover
July 14, 2014 by Brad Perriello
Allergan went on the offensive again today in its battle against a hostile takeover bid by Valeant Pharmaceuticals and its hedge fund partner, Pershing Square Capital Management, demanding more transparency from Valeant about its business and prospects for growth – even as Valeant today filed a pre-merger notification with the U.S. Federal Trade Commission.
Allergan said it wants answers to questions raised by it and “important members of the investment community” about “Valeant’s anemic organic growth driven by unsustainable price increases, among other fundamental business model issues.” Read more
Abbott to deal pharma line to Mylan for $5.3B
July 14, 2014 by Brad Perriello
Mylan said today that it agreed to pay $5.3 billion to Abbott for its non-U.S. developed markets specialty and branded generics business in an all-stock deal.
Once consummated, the deal would see Abbott receive 105 million shares of the combined company, for a roughly 21% stake in the new entity. Read more
Exo-suit maker ReWalk files for $57.5M IPO
July 10, 2014 by Arezu Sarvestani
ReWalk Robotics, formerly Argo Medical Technologies, is preparing an initial public offering worth up to $57.5 million, according to regulatory filings.
The company, which just last month won FDA approval for the 1st robotic exo-suit for helping patients with lower-body paralysis walk upright, has yet to release full pricing for the IPO or detail how many shares it plans to offer. The company plans to trade on the Nasdaq exchange under the symbol RWLK. Read more
Intersect ENT sets terms for $65M IPO
July 14, 2014 by Brad Perriello
Intersect ENT said today that it hopes to raise as much as $65 million in an initial public offering of 5 million shares.
Intersect, which makes drug-eluting devices designed to treat ear, nose & throat conditions, said it plans to price the shares at $11 to $13 apiece, meaning the offering could raise between $55 million and $65 million. Read more
